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Abstract
Purpose Existing health technology assessment methods can
be time-consuming and complicated to use in practice. EVal-
uation of pharmaceutical Innovations with regard to Thera-
peutic Advantage (EVITA) is a recently developed drug as-
sessment strategy that provides a detailed and clinically rele-
vant evaluation of new agents compared to standard therapies.
We therefore sought to use EVITA to evaluate eight novel
agents recently introduced to clinical practice or in late-stage
trials for the treatment of prostate cancer, metastatic melano-
ma, or systemic lupus erythematosus (SLE).
Methods Eight agents (abiraterone, enzalutamide, sipuleucel-
T, Prostvac, radium 223, ipilimumab, vemurafenib, and beli-
mumab) were selected for study using the EVITA algorithm.
A comprehensive literature search was performed to find
clinical trial data, which were then classified using the EVITA
protocol. EVITA was also compared to results from health
technology assessments (HTAs) or reimbursement decisions.
Results The EVITA scores for the eight drugs ranged from 5.5
to 9: all the selected agents are therefore classed as ‘recom-
mended’ and are likely to produce a therapeutic advantage. In
particular, vemurafenib is likely to be highly beneficial to
patients with metastatic melanoma and radium 223 to patients
with metastatic prostate cancer affecting the bone. The EVITA
results were generally concordant with HTAs.
Conclusions All the agents show favourable EVITA scores
and are therefore recommended for clinical practice. EVITA is
an easy-to-use tool that provides clinical context to the assess-
ment of newly introduced agents and can be easily used by
non-specialists.
Keywords EVITA . Health technology assessment .
Metastaticmelanoma . Prostate cancer . Systemic lupus
erythematosus
Introduction
Many new therapeutic agents introduced to the market claim
to be innovative, but their actual clinical benefit is often
uncertain at the time of regulatory approval [1]. Several mul-
tifactorial health technology assessment methods are used to
evaluate the likely benefit of new therapies, such as those
issued by the National Institute for Health and Clinical Excel-
lence (NICE) in the UK, the German Institut für Qualität und
Wirtschaftlichkeit im Gesundheitswesen, and the evaluation
strategy proposed by Caprino and Russo [2]. These assess-
ments are comprehensive but time-consuming and can be
complicated for non-specialists to use. Other evaluation strat-
egies, such as the classification by Fricke and Klaus [3], do not
require new agents to show a clinically significant advantage
over standard treatments in order to be deemed ‘innovative’.
There is a need for a simple and transparent tool that evaluates
the benefits and risks of new drugs over existing treatments.
EValuation of pharmaceutical Innovations with regard to
Therapeutic Advantage (EVITA) is a recently developed drug
assessment strategy that provides a time-oriented and detailed
evaluation of new agents compared to standard therapies [1].
Data from eligible randomised controlled trials are used in the
EVITA algorithm, which takes into account an efficiency
profile, a risk profile, and a trial setting, the latter being used
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to contextualise the clinical validity of the efficiency and risk
profile results. The overall numerical result is visualised as a
colour-coded bar graph that shows the benefit of the new
treatment and is easily interpretable, even by non-specialists.
Another advantage of EVITA is that since the algorithm does
not depend on the chemical composition and definition of a
new chemical entity (NCE), it can be applied to any new
therapeutic modality introduced into clinical practice,
including small molecule inhibitors, immunomodulatory
agents, or radionuclides.
Although EVITA has been used to assess a few commonly
used drugs ([1] and http://www.hta.uni-bremen.de/index.php/
projekte/evita/evita-english), the algorithm has yet to be
applied to cutting-edge agents that are emerging as potential
therapies for life-threatening diseases.
Here, we use EVITA to evaluate eight recently introduced
agents (abiraterone, enzalutamide, sipuleucel-T, Prostvac, ra-
dium 223, ipilimumab, vemurafenib, and belimumab) already
approved for clinical use or still in phase III trials; these agents
are used to treat castration-resistant prostate cancer, metastatic
melanoma, or systemic lupus erythematosus (SLE). The pri-
mary objective of this study is to assess the benefits and risks
of new drugs compared to existing standard treatments and the
secondary objective is to determine the practicality and valid-
ity of EVITA by comparing our results to existing Health
Technology Assessment (HTA) reports.
Materials and methods
Eight agents (abiraterone, enzalutamide, sipuleucel-T,
Prostvac, radium 223, ipilimumab, vemurafenib, belimumab)
were selected for study using EVITA. Approval of the local
ethics committee was not required since the study did not
directly require the participation of human study subjects
(EKBB).
EVITAwas conducted as described in [1]. EVITA requires
input of clinical trial data with a Jadad score (used to assess the
methodological quality of a clinical trial [4]) of at least three.
A systematic literature search of the eight study drugs was first
conducted using PubMed and Google Scholar. The EVITA
algorithm comprises four main steps for each drug: (1) classi-
fication of the main therapeutic aim of the new agent (pre-
vention or treatment), with treatment then being divided into
four categories (Table 1); (2) calculation of the absolute risk
reduction (ARR; in this study, the ARR in OS after 1 year) or
the numbers needed to treat (NNT) for each therapy (i.e. the
new agent versus standard treatment or placebo) to produce a
modifier score (Table 2); (3) comparison of the efficiency of
the two treatments (new agent versus standard treatment or
placebo; Table 3), with the efficiency score then being calcu-
lated by adding the modifier to the outcome results (agents
showing benefit in multiple trials have higher scores); and
finally (4) comparing the adverse effects exhibited by the two
therapies (new agent versus standard treatment or placebo)
with each grade of adverse effect (1–5) to derive a risk score
for both groups (Table 4). The overall score is the sum of the
efficiency score and the risk score, which is then visualised as
a colour-coded bar graph (see examples in Fig. 2). Since the
design of each study varied, each study needed to be assigned
a trial setting using the flowchart shown in Fig. 1. Addition-
ally, each drug was described in an EVITA datasheet for easy
reference (Supplementary File 1).
The EVITA scores of the eight drugs studied were com-
pared to the Health Technology Assessment (HTA) reports
and reimbursement decision reports available on the
Turning Research Into Practice (TRIP) database (http://
www.tripdatabase.com/). Each concordant or discordant
result was discussed.
Results
Overall findings
Each drug was evaluated separately and a summary EVITA
assessment compiled for each agent (Fig. 2 and Supplemen-
tary File 1). The EVITA scores for the eight drugs ranged from
Table 1 Therapeutic aim and disease category
Prevention To reduce risk of disabling or impairing events
Treatment To cure diseases, to substitute missing substances
indispensable to life, to modify or relieve symptoms
Severity grading of the diseases:
I. acute life-threatening or severe chronic disease
II. rehabilitation
III. less severe acute or chronic disease
IV. application outside a treatment context
Table 2 Modifier
ARR absolut risk
reduction, NNT number
needed to treat
NNT ARR Modifier
Prevention
<20 5–100 % 2.0
20–<50 <5 % 1.75
50–<100 <2 % 1.5
100–<175 <1 % 1.25
175–<300 <0.57 % 1.0
300–<500 <0.33 % 0.75
500–<1,000 <0.2 % 0.5
≥1,000 <0.1 % 0.25
Treatment
<3 >30 % 2.0
3–<10 10–30 % 1.5
≥10 <10 % 1.0
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5.5 to 9 (Fig. 2), i.e. all the selected agents are recommended.
The ‘therapeutic aim’ (step 1) for all the drugs under study
was treatment category 1, since all had been developed for
life-threatening chronic diseases. The efficiency scores ranged
from 6 to 9, which was in part due to the different numbers of
randomised studies available and slightly different modifiers
(ranging from 1 to 1.5). Each study had a significant patient-
relevant outcome. All risk scores were 0 with the exception of
vemurafenib and ipilimumab, which had risk scores of 0.5 and
−1, respectively, since they did not have a frequency above
10 % for every grade of adverse event. There was one A1 trial
setting (vemurafenib), five A2 settings (abiraterone,
ipilimumab, enzalutamide, radium 223, and belimumab),
and two question marks (Prostvac and sipuleucel-T), since
these two therapies were not compared to the standard treat-
ment or with placebo as an add-on to the standard therapy;
these results are therefore of questionable validity.
The use of EVITAwas generally time efficient and suitable
for non-specialists, with the most time-consuming element
being literature searching and interpretation. Overall, 25 dif-
ferent studies and reviews were analysed in this study. Calcu-
lation of the modifier was not always trivial since the ARRs
and NNTwere not always directly available; in these studies,
the data of the patients in both treatment arms (new agent
versus standard treatment or placebo) still alive at 1 year were
extracted and the 1-year ARR and OS calculated. Accurately
identifying the separate frequencies of the grades 3–5 adverse
events was sometimes difficult since they were often described
together; in these cases, the frequencies of the adverse effects
of the new drugs were nearly the same as the ones of the
standard treatments or placebo, and therefore their distribution
over grades 3–5 were assumed to be the same (risk score 0).
With respect to validity, the EVITA results were compared
with HTA outcomes or drug reimbursement decisions from
the TRIP database (Supplementary File 2). Most of the reports
were positive and concordant with EVITA. Negative results
were mainly based on inappropriate or missing dossiers or an
unfavourable health economic analysis. However, EVITA
does not include economic data in its assessment and can
therefore only determine the clinical benefit of a new drug.
In cases where no decision had yet beenmade by the decision-
making bodies (Sipuleucel-T and Prostvac), EVITA al-
ready had a question mark (i.e. questionable validity)
for the trial setting.
Specific agents
Abiraterone
One randomised double-blind phase III study of
abiraterone was identified [5]. In this study, abiraterone
Table 4 Risk profile
Severity grading Frequency Ther. inv. Ther. stand.
Adverse events (AE)
Grades 5+4
(death related to AE or
life-threatening AE or
disabling AE)
≥10 % −4 −4
≥1 % −3 −3
≥0.1 % −2 −2
<0.1 % −1 −1
0 0 0
Grade 3
(severe and undesirable AE) ≥10 % −2.5 −2.5
≥1 % −2 −2
≥0.1 % −1 −1
<0.1 % 0 0
0 0 0
Grades 2+1
(moderate AE or mild AE) ≥10 % −1.5 −1.5
≥1 % −1 −1
≥0.1 % −0.5 −0.5
<0.1 % 0 0
0 0 0
Interactions
Frequent or serious clinical consequence −2 −2
Occasional or may have clin. consequence −1.5 −1.5
Dose change −1 −1
Unlikely/probably or no clin. consequence 0 0
No information available −1 −1
Sum
Risk score
ther. inv. therapy investigated, ther. stand. therapeutic standard
Table. 3 Efficiency profile
RCTs showing evidence of n. of
RCT
p. rel.
outcome
Surr.
outcome
Superiority 0 0 0
1 +5 +2.5
≥2 +7.5 +3.75
Non-inferiority/equivalence
(in the presence of other
RCT showing superiority)
0 0 0
1 −1.67 −0.83
≥2 −2.5 −1.25
Non-inferiority/equivalence
(in the absence of other
RCT)
any 0 0
Non-inferiority/equivalence
(in the presence of other
RCT showing inferiority)
0 0 0
1 +1.67 +0.83
≥2 +2.5 +1.25
Inferiority 0 0 0
1 −5 −2.5
≥2 −7.5 −3.75
Sum
Modifier
Efficiency score
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was compared to placebo as an add-on to the standard
treatment (docetaxel); the trial setting was therefore A2.
Abiraterone is indicated for prolonging the lifespan of
patients with castration-resistant prostate cancer; the
treatment category was therefore 1. The ARR in OS at
1 year was 13 %, resulting in a modifier of 1.5. The
primary endpoint was median OS, which was signifi-
cantly longer in the abiraterone cohort than in the pla-
cebo cohort (15.8 versus 11.2 months), earning an effi-
ciency score of 6.5. The adverse effects of both treat-
ments were similar, thus the risk score was 0, resulting
in a final score of 6.5.
Radium 223
A randomised, multicentre, placebo-controlled phase II study
[6] and a phase III randomised trial [7] were identified; in both
of these, radium 223 was compared with placebo. Since there
was no standard treatment for the specific indication (treat-
ment of bone metastases in castration-resistant prostate can-
cer), the trial setting was A2. Since radium 223 should im-
prove both the quality and quantity of life, the treatment
category was 1. The ARR in OS at 50 weeks (no data were
available at 1 year) was 16 %, resulting in a modifier of 1.5.
Both studies revealed a significantly improved median OS
(phase II: 15 versus 10.7 months; phase III 14 versus
11.2 months), earning an efficiency score of 9. The adverse
effects of both treatments were similar thus the risk score was
0, resulting in a final score of 9.
Enzalutamide
One randomised, double-blind phase III study was found [8]
in which enzalutamide was compared to placebo as add-on to
the standard treatment (docetaxel), a trial setting of A2. Since
enzalutamide was developed to prolong the lifespan of pa-
tients with castration-resistant prostate cancer, the treatment
category was 1. The ARR in OS at 1 year was 30 %, resulting
in a modifier of 1.5. The primary endpoint was defined as the
median OS, which was significantly better in the enzalutamide
group than in the placebo group (18.4 versus 13.6 months),
earning an efficiency score of 6.5. The adverse effects of both
treatments were similar, thus the risk score was 0, resulting in
a final score of 6.5.
Fig. 1 Flowchart showing the decision tree used to define EVITA trial settings
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Sipuleucel-T
Three randomised, double-blind phase III studies were iden-
tified. Two were analysed together, since their study design
was identical [9]. Sipuleucel-T was not compared to the stan-
dard treatment (docetaxel) or placebo, and therefore, the trial
setting was a question mark. The treatment category was
defined as 1, since sipuleucel-T should improve survival of
patients with castration-resistant prostate cancer. The ARR in
OS at 1 year was 7 % in the integrated study [9] and 8 % in the
Kantoff et al. [10] study, resulting in a modifier of one. Both
studies showed a significant reduction in the RR of death
(33 % in the integrated study, 22% in the Kantoff et al. study),
earning an efficiency score of 8.5. The adverse effects of both
treatments were similar, thus the risk score was 0, and the final
score was 8.5.
Prostvac
Two randomised, double-blind phase II studies were
identified [11, 12]. Since the control group was missing
in Gulley et al. [12] and all cohorts received Prostvac
(with four different doses of immune adjuvants), this
study was not included in the present analysis. In the
other study [11], Prostvac was not compared to the
standard treatment (docetaxel) or to placebo, and there-
fore, the trial setting was a question mark. Prostvac was
developed to prolong the survival of patients with
castration-resistant prostate cancer, and therefore, the
treatment category was 1. The ARR in OS at 1 year
was 4 %, resulting in a modifier of 1. At three years
post-treatment, Prostvac patients had a significantly im-
proved OS (30 versus 17 %), earning an efficiency
score of 6. The adverse effects of both treatments were
similar, thus the risk score was 0, and the final score
was 6.
Ipilimumab
One randomised, double-blind phase III study was
identified [13]. Ipilimumab was compared to placebo
as add-on to the standard treatment (dacarbazine), and
therefore, the trial setting was A2. The treatment cate-
gory was classified as 1, since metastatic melanoma is
a life-threatening disease. The ARR in OS at 1 year
was 11 %, resulting in a modifier of 1.5. The primary
endpoint was defined as the median OS, which was
significantly longer in the ipilimumab cohort than in
the placebo cohort (11.2 versus 9.1 months), earning an
efficiency score of 6.5. The adverse effects of both
treatments were similar except for grades 4 and 5
(ipilimumab group 16.2 % and placebo group 9.2 %);
therefore, the risk score was −1, and the final score
was 5.5.
Fig. 2 Summary diagram showing the EVITA scores of the eight agents studied
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Vemurafenib
One randomised, multinational phase III study was identified
[14]. Since vemurafenib was compared to the standard treat-
ment (dacarbazine), the trial setting was A1. The treatment
category was classified as 1, since metastatic melanoma is a
life-threatening disease. The ARR in OS at six months was
20%, resulting in a modifier of 1.5. The OS at 1 year could not
be evaluated because the dacarbazine group was allowed to
cross over to vemurafenib, since the primary endpoints (OS
and progression-free survival (PFS)) had already met the pre-
specified criteria for statistical significance; the efficiency
score was therefore 6.5. The vemurafenib group had a grades
2–3 adverse effects frequency of greater than 10 % and
adverse events of grade 4–5 in less than 1 % of the patients.
In the dacarbazine group, there were less grade 3 (≥1 %)
events but more grade 4 and 5 (≥1 %) events. Therefore, the
risk score was 0.5 resulting in a final score of 7.
Belimumab
Two randomised, double-blind, phase III studies were identi-
fied [15, 16]; in both studies (at two different doses 10 and
1 mg/kg), belimumab was compared to placebo as an add-on
to the standard treatment (individually adapted), thus the trial
setting was A2. The treatment category was 1, since SLE is a
severe chronic disease. Since there were no OS data, we took
the ARR of the SRI (systemic lupus erythematosus responder
index), which is based on the overall severity or development
of substantial disease activity in new organ systems [17]. The
ARRs of the SRI at 1 year were 14 and 12% (10 mg/kg) and 9
and 7 % (1 mg/kg) in the two trials, thus the modifier was 1.5.
Since both studies showed that, significantly, more people
were responsive to the 10 mg/kg belimumab group than in
the placebo group; the efficiency score was 9. The adverse
effects of both treatments were similar, thus the risk score was
0, and the final score was 9.
Discussion
EVITA is a recently described algorithm designed to assess
the efficiency of new agents recently introduced into clinical
practice in trials. The methodology is time efficient and sim-
ple, yet still detailed enough to produce meaningful and useful
results. Here we examine the use of EVITA for eight
novel therapies in order to assess their clinical utility
using this algorithm.
These particular agents were developed to treat three dif-
ferent diseases: castration-resistant prostate cancer, metastatic
melanoma, and systemic lupus erythematosus (SLE); all three
of these diseases are acutely life-threatening or severely
chronic. Prostate cancer is the third leading cause of male
cancer-related death in Europe [18]. Although many men
initially respond to androgen-deprivation therapy, progression
eventually occurs. Following cytotoxic chemotherapy with
docetaxel, the median overall survival (OS) is less than two
years [19, 20]; new treatment options are therefore needed.
Metastatic melanoma is responsible for three-quarters of all
deaths caused by skin cancer [21]. Currently, dacarbazine, the
only chemotherapeutic agent approved by the FDA for the
treatment of metastatic melanoma, is considered standard
treatment, but it is only associated with a median OS of 5.6
to 7.8 months in phase 3 studies [22–25] and has never
actually been shown to improve survival in randomised con-
trolled trials [26, 27]. However, ipilimumab and vemurafenib
are two new emerging targeted therapies showing clinical
promise for metastatic melanoma. Finally, SLE is a chronic
autoimmune disorder that markedly impairs patients’ quality
of life [28]. Although therapies commonly used in clinical
practice, such as corticosteroids, hydroxychloroquine, and
immunosuppressive drugs, all improve outcomes for patients
with SLE, they are associated with significant side effects and
more effective treatments would be desirable [15]. Circulating
B cell activating factor (BAFF) is commonly elevated in SLE
and correlates with disease activity and anti–double-stranded
DNA (anti-dsDNA) antibody concentrations [29–31].
Inhibiting BAFF is therefore a novel approach for treating
SLE [32].
In contrast to other drug assessment systems, in which new
agents do not need to show a clinically significant advantage
over standard treatments [1], EVITA compares the new agent
with the standard treatment or with placebo, thereby providing
clinical relevance and context rather than simply the details of
the chemical innovation; proving clinical benefit is ultimately
what matters in terms of clinical practice. Important clinical
parameters such as adverse effects are included and vary the
final result, which is of real clinical importance when
assessing therapeutic index in vulnerable and often very ill
patients. Assessment of the trial setting is an important
parameter to include to assess both the validity of the
result and indicate how advanced the drug is in clinical
development, providing an indicator of whether more
research may be needed for licensing. Additionally, the
EVITA protocol is transparent, easily reproducible by
anyone with access to the clinical studies, and the final
score can easily be adapted when new studies are pub-
lished. EVITA is therefore a dynamic tool that can be
used to chart the progress of drug development during
the clinical phases of testing.
In our study, no EVITA result was negative. This might be
due to the existence of publication bias, which is known to
lead to more positive pivotal trials being published. Puntmann
et al. do, however, report negative EVITA results for
pioglizone (for diabetes mellitus) and bupropion (for major
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depression) due to a lack of proven superiority of patient-
relevant outcomes or an unfavourable risk profile [1].
We did experience some difficulties when using EVITA
and it does have some limitations. In cases where there are two
studies with the same design conducted in two different
groups of patients [e.g. lenalidomide in 1], the original algo-
rithm dictates that these should count as one study, whereas
we suggest that in this situation the reproducibility of the
result increases the level of confidence in the agent and should
therefore carry more weight than a single study. Generally, it is
not possible to weight the methodical differences between
studies, thus they can be of different quality but still generate
the same EVITA score. From a practical perspective, the
extraction of grades 4 and 5 adverse events was often difficult
since many studies count them with grade 3 adverse events.
Generating the ARRs or NNTs was difficult when these
measurements were not specifically detailed in the studies
and required a manual calculation that might be prone to error.
With respect to the different diseases studied, all five of the
newly developed agents for castration-resistant prostate can-
cer (abiraterone, radium 223, enzalutamide, Prostvac, and
sipuleucel-T) had high EVITA scores, indicating that these
are highly effective agents. The five agents represent three
different treatment modalities: two small molecular inhibitors
targeting the androgen pathway (abiraterone and
enzalutamide), two tumour vaccines (Prostvac and
sipuleucel-T), and one radionuclide (radium 223). This diver-
sity of approach might be important for targeting the disease
using multi-modal therapy, and it is important to note that
EVITA is capable of producing interpretable and comparable
results for very different treatment modalities. Abiraterone,
enzalutamide, and radium 223 all appear to be promising
agents, since their EVITA scores were 6.5 or above. However,
the Prostvac and sipuleucel-T results need interpreting with
caution due to the suboptimal nature of the underlying trials
(question marks), and further clinical research on these agents
is required. This is also in line with the evaluations available in
the TRIP database, where many evaluations have yet to decide
whether the drug should be recommended or not. However, if
the economic analysis was a major reason for a negative
response, this will not be accounted for by EVITA and will
have no influence on the EVITA result. The EVITA evalua-
tions for these drugs would need to be updated when further
data become available.
Both the newly developed agents for metastatic melanoma
(ipilimumab and vemurafenib) were effective and could be
recommended (ipilimumab 5.5 and vemurafenib 7). Even
after 6 months, the vemurafenib-treated group had an ARR
in OS of 20 % compared to the placebo group, whereas
ipilimumab showed a reduction of 11 % at 1 year. However,
these two drugs cannot be directly compared since
vemurafenib is given specifically to patients whose tumours
harbour a BRAF mutation, whereas ipilimumab is not
subdivided on the basis of a molecular test. Therefore,
vemurafenib can only be considered of benefit in BRAF
mutation carriers while ipilimumab is applicable to the
wider population.
Belimumab was highly effective for the treatment of SLE
and is highly recommended (EVITA score 9). Other available
therapies improve outcomes for patients with SLE but have
unfavourable side-effect profiles [15]. Belimumab showed a
significant ARR in the SLE Responder Index (SRI) (which
takes quality of life into account), and therefore, the patients
benefit not only from a prolonged lifespan but also from a
higher health-related quality of life. Inhibition of BAFF with
belimumab might represent a step forward in the management
of patients with SLE.
In conclusion, here, we have applied the newly developed
EVITA algorithm to the assessment of eight highly promising
new agents being used to treat life-threatening serious or
chronic diseases. All the agents show favourable EVITA
scores and are therefore recommended for clinical practice.
EVITA is an easy-to-use tool that provides clinical context to
the assessment of newly introduced agents and can be easily
used by non-specialists.
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